← Back to Screener
Invivyd, Inc. Common Stock (IVVD)
Price$1.68
Favorite Metrics
Price vs S&P 500 (26W)-9.88%
Price vs S&P 500 (4W)16.59%
Market Capitalization$492.08M
All Metrics
Book Value / Share (Quarterly)$0.86
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.21
Price vs S&P 500 (YTD)-33.69%
Gross Margin (TTM)92.99%
Net Profit Margin (TTM)-98.25%
EPS (TTM)$-0.36
10-Day Avg Trading Volume4.94M
EPS Excl Extra (TTM)$-0.36
EPS (Annual)$-0.30
ROI (Annual)-21.73%
Gross Margin (Annual)92.99%
Cash / Share (Quarterly)$0.80
Revenue Growth QoQ (YoY)24.51%
ROA (Last FY)-18.96%
EBITD / Share (TTM)$-0.32
ROE (5Y Avg)-98.74%
Operating Margin (TTM)-103.99%
Cash Flow / Share (Annual)$-0.21
P/B Ratio2.04x
P/B Ratio (Quarterly)2.83x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)4.97x
ROA (TTM)-34.48%
EPS Incl Extra (Annual)$-0.30
Current Ratio (Annual)7.24x
Quick Ratio (Quarterly)7.07x
3-Month Avg Trading Volume3.51M
52-Week Price Return269.19%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)9.21x
Asset Turnover (Annual)0.19x
52-Week High$3.07
EPS Excl Extra (Annual)$-0.30
26-Week Price Return-1.14%
Quick Ratio (Annual)7.07x
13-Week Price Return-33.08%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)7.24x
Enterprise Value$265.39
Asset Turnover (TTM)0.35x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-98.25%
Cash / Share (Annual)$0.80
3-Month Return Std Dev103.71%
Net Income / Employee (TTM)$-0
ROE (Last FY)-21.73%
EPS Basic Excl Extra (Annual)$-0.30
Receivables Turnover (TTM)4.30x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.36
ROI (TTM)-48.65%
P/S Ratio (TTM)9.21x
Revenue / Share (Annual)$0.31
Price vs S&P 500 (52W)234.10%
Year-to-Date Return-29.55%
5-Day Price Return1.16%
EPS Normalized (Annual)$-0.30
ROA (5Y Avg)-67.28%
Net Profit Margin (Annual)-98.25%
Month-to-Date Return33.85%
EBITD / Share (Annual)$-0.32
Operating Margin (Annual)-103.99%
ROI (5Y Avg)-98.74%
EPS Basic Excl Extra (TTM)$-0.36
P/B Ratio (Annual)2.83x
Pretax Margin (TTM)-98.25%
Book Value / Share (Annual)$0.86
Price vs S&P 500 (13W)-35.94%
Beta0.97x
Revenue / Share (TTM)$0.19
ROE (TTM)-48.65%
52-Week Low$0.46
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.10
4.10
4.10
4.10
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IVVDInvivyd, Inc. Common Stock | 9.21x | — | 92.99% | — | $1.68 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Invivyd Inc is a biopharmaceutical company developing monoclonal antibody therapies for serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), holds FDA emergency use authorization for COVID-19 prevention in immunocompromised patients. The company is advancing pipeline candidates including VYD2311 for COVID-19 and VBY329 for RSV.